[go: up one dir, main page]

NO971517L - Peptides and pharmaceutical compositions comprising them - Google Patents

Peptides and pharmaceutical compositions comprising them

Info

Publication number
NO971517L
NO971517L NO971517A NO971517A NO971517L NO 971517 L NO971517 L NO 971517L NO 971517 A NO971517 A NO 971517A NO 971517 A NO971517 A NO 971517A NO 971517 L NO971517 L NO 971517L
Authority
NO
Norway
Prior art keywords
cells
peptides
pharmaceutical compositions
idiotypic
activity
Prior art date
Application number
NO971517A
Other languages
Norwegian (no)
Other versions
NO971517D0 (en
Inventor
Irun I Cohen
Dana Elias
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO971517D0 publication Critical patent/NO971517D0/en
Publication of NO971517L publication Critical patent/NO971517L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates generally to peptide sequences, and methods of their use, which sequences modulate the activity of anti-idiotypic T cells. The activity of the anti-idiotypic T cells of interest is related to the ability of these T cells to recognize anti-p277 T cells. The peptides of the present invention thus comprise important tools in the effort to diagnose, prevent, alleviate or treat disease related to insulin-dependent diabetes mellitus (IDDM).
NO971517A 1994-10-07 1997-04-03 Peptides and pharmaceutical compositions comprising them NO971517L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11119694A IL111196A0 (en) 1994-10-07 1994-10-07 Peptides and pharmaceutical compositions comprising them
PCT/US1995/012686 WO1996011214A1 (en) 1994-10-07 1995-10-10 Peptides and pharmaceutical compositions comprising them

Publications (2)

Publication Number Publication Date
NO971517D0 NO971517D0 (en) 1997-04-03
NO971517L true NO971517L (en) 1997-05-22

Family

ID=11066614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971517A NO971517L (en) 1994-10-07 1997-04-03 Peptides and pharmaceutical compositions comprising them

Country Status (15)

Country Link
EP (1) EP0783524B1 (en)
JP (1) JPH10507345A (en)
KR (1) KR100381711B1 (en)
AT (1) ATE289611T1 (en)
AU (1) AU708301B2 (en)
CA (1) CA2201935A1 (en)
CZ (1) CZ103197A3 (en)
DE (1) DE69534024T2 (en)
FI (1) FI971427A7 (en)
HU (1) HUT77484A (en)
IL (1) IL111196A0 (en)
NO (1) NO971517L (en)
PL (1) PL319831A1 (en)
SK (1) SK44197A3 (en)
WO (1) WO1996011214A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
DK2319928T3 (en) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimeric thrombopoietic peptidomimetics that bind to MPL receptor and have thrombopoietic activity
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
CN101103045B (en) 2004-09-24 2015-11-25 安姆根有限公司 The Fc molecule modified
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2015145449A2 (en) * 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
SI3560954T1 (en) 2014-04-03 2021-11-30 Igm Biosciences, Inc. Modified j-chain
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
JP7058213B2 (en) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド Bonded molecule with modified J chain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof

Also Published As

Publication number Publication date
CZ103197A3 (en) 1997-09-17
NO971517D0 (en) 1997-04-03
EP0783524A1 (en) 1997-07-16
DE69534024T2 (en) 2006-01-12
FI971427L (en) 1997-05-26
PL319831A1 (en) 1997-09-01
EP0783524B1 (en) 2005-02-23
AU3946295A (en) 1996-05-02
KR970706306A (en) 1997-11-03
FI971427A0 (en) 1997-04-04
DE69534024D1 (en) 2005-03-31
HUT77484A (en) 1998-05-28
WO1996011214A1 (en) 1996-04-18
FI971427A7 (en) 1997-05-26
KR100381711B1 (en) 2003-07-16
JPH10507345A (en) 1998-07-21
IL111196A0 (en) 1994-12-29
SK44197A3 (en) 1997-11-05
AU708301B2 (en) 1999-07-29
EP0783524A4 (en) 2000-05-17
ATE289611T1 (en) 2005-03-15
CA2201935A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
BR9710452A (en) Anïïlogos of exendin processes for its preparation and medicines containing the same
CA2219988A1 (en) Cd16-ii variants
NO930011D0 (en) INDIVIDUAL BOI OLIGOMS LIBRARY AND PROCEDURE FOR SYNTHESIS AND USE THEREOF
NO971517D0 (en) Peptides and pharmaceutical compositions comprising them
IS4510A (en) Peptide p277 analogues and pharmaceutical compositions containing them, for the treatment or diagnosis of diabetes
HUP9901688A2 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
RU94041224A (en) PEPTIDES WITH ORGAN-PROTECTIVE ACTIVITY, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND THEIR USE IN THERAPY
DK1025849T3 (en) Methods for detecting and treating individuals having abnormal cells expressing HLC-A2 / tyrosinase peptide antigens
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
ID23184A (en) SALES OF BPC PEPTIDES WITH ORGANOPROTECTIVE ACTIVITIES FOR THE PROCESS OF MAKING AND USING IT IN THERAPY
DE69738600D1 (en) NEUROACTIVE PEPTIDES
ATE183652T1 (en) SYNTHETIC PEPTIDES FOR THE TREATMENT OF MYASTHENIA GRAVIS
DK0722460T3 (en) Peptide derivatives that are therapeutically active in the blood coagulation cascade, methods of preparing them, and pharmaceuticals
DK0423326T3 (en) Hitherto unknown physiologically active peptide and calcium metabolism regulator comprising the peptide as effective organism
DE69832075D1 (en) USE OF EPROSARTAN FOR THE TREATMENT OF ISOLATED SYSTOLIC BLOOD HIGH PRESSURE
NO900255L (en) PEPTIDES WITH T-CELL HELP ACTIVITY.
TH31634A (en) New peptide suitable for use in antigen-specific immune suppression therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application